Legend Biotech Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Legend Biotech Corp.
As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta.
The antibody-drug conjugate now looks set for US approval, but its limitations leave plenty of scope for CAR-T and bispecific rivals.
- Gene Therapy, Cell Therapy